Ken Griffin Rain Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$0.84 - $1.22 $15,708 - $22,814	-18,700 Reduced 94.44%	1,100 $1,000
Q3 2023 Nov 14, 2023	SELL	$0.82 - $1.42 $14,104 - $24,424	-17,200 Reduced 46.49%	19,800 $17,000
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $16,568 - $150,936	15,200 Added 69.72%	37,000 $44,000
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $160,839 - $258,129	20,700 Added 1881.82%	21,800 $190,000
Q4 2022 Feb 14, 2023	BUY	$5.52 - $8.48 $6,071 - $9,328	1,100 New	1,100 $8,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.